WO2023079466A3 - Treatment of sequelae of coronavirus infections - Google Patents

Treatment of sequelae of coronavirus infections Download PDF

Info

Publication number
WO2023079466A3
WO2023079466A3 PCT/IB2022/060575 IB2022060575W WO2023079466A3 WO 2023079466 A3 WO2023079466 A3 WO 2023079466A3 IB 2022060575 W IB2022060575 W IB 2022060575W WO 2023079466 A3 WO2023079466 A3 WO 2023079466A3
Authority
WO
WIPO (PCT)
Prior art keywords
sequelae
coronavirus infection
treatment
treating
invention features
Prior art date
Application number
PCT/IB2022/060575
Other languages
French (fr)
Other versions
WO2023079466A2 (en
Inventor
Gabriel Gojon-Zorrilla
Gabriel Gojon-Romanillos
Original Assignee
Sulfagenix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfagenix, Inc. filed Critical Sulfagenix, Inc.
Publication of WO2023079466A2 publication Critical patent/WO2023079466A2/en
Publication of WO2023079466A3 publication Critical patent/WO2023079466A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention features compositions and methods for treating sequelae of coronavirus infection, e.g., betacoronavirus. The present invention features a method of treating or preventing one or more sequelae of a coronavirus infection. The method includes administering to the subject a pharmaceutical composition including elemental alpha sulfur, highly polar components, and a pharmaceutically acceptable excipient in an amount and for a duration sufficient to treat or prevent the one or more sequelae of the coronavirus infection.
PCT/IB2022/060575 2021-11-03 2022-11-03 Treatment of sequelae of coronavirus infections WO2023079466A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163275016P 2021-11-03 2021-11-03
US63/275,016 2021-11-03

Publications (2)

Publication Number Publication Date
WO2023079466A2 WO2023079466A2 (en) 2023-05-11
WO2023079466A3 true WO2023079466A3 (en) 2023-06-08

Family

ID=86240909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/060575 WO2023079466A2 (en) 2021-11-03 2022-11-03 Treatment of sequelae of coronavirus infections

Country Status (1)

Country Link
WO (1) WO2023079466A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064286A1 (en) * 2011-09-14 2015-03-05 Emory University Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
WO2021180655A1 (en) * 2020-03-11 2021-09-16 Om Pharma Sa 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064286A1 (en) * 2011-09-14 2015-03-05 Emory University Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof
WO2021180655A1 (en) * 2020-03-11 2021-09-16 Om Pharma Sa 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAZA HUSSAIN AHMED; TARIQ JAVERIA; AGARWAL VIKAS; GUPTA LATIKA: "COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases", RHEUMATOLOGY INTERNATIONAL, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 41, no. 2, 1 January 1900 (1900-01-01), Berlin/Heidelberg, pages 257 - 273, XP037344915, ISSN: 0172-8172, DOI: 10.1007/s00296-020-04759-2 *
YUSUF I H, SHARMA S, LUQMANI R, DOWNES S M: "Hydroxychloroquine retinopathy", EYE, NATURE PUBLISHING GROUP, GB, vol. 31, no. 6, 1 June 2017 (2017-06-01), GB , pages 828 - 845, XP093071555, ISSN: 0950-222X, DOI: 10.1038/eye.2016.298 *

Also Published As

Publication number Publication date
WO2023079466A2 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
JOP20220179A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BRPI0520588B8 (en) use of pharmaceutical compositions for the treatment of inner ear diseases
AR060089A1 (en) PAIN TREATMENT
MX2022002196A (en) Niclosamide delayed-release composition and antiviral use thereof.
MX2022015601A (en) Compound for the treatment of coronaviral infections.
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
UA81625C2 (en) Use of rotigotin for trans-epicutaneous treating restless leg syndrome
MX2022009197A (en) Methods of treatment for alpha-1 antitrypsin deficiency.
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
PH12021550713A1 (en) Medicament for the treatment of chronic cough
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2021009219A (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
WO2006113718A3 (en) Compositions for the treatment of neoplasms
BR112023021131A2 (en) ESSENTIAL TREMOR TREATMENT
MX2020008360A (en) Crystalline form of bictegravir sodium.
MX2022005388A (en) Pyrrolidine and piperidine compounds.
WO2023079466A3 (en) Treatment of sequelae of coronavirus infections
MX2022000433A (en) Fusion toxin proteins for treatment of diseases related to cmv infections.
MX2021011986A (en) Methods of treating neuropathic pain.
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2021014634A (en) Wide-spectrum antibacterial pharmaceutical formulations comprising lysozyme and methods of using the same.
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22889549

Country of ref document: EP

Kind code of ref document: A2